Global Innovation in Emerging Economies

Total Page:16

File Type:pdf, Size:1020Kb

Global Innovation in Emerging Economies Global Innovation in Emerging Economies In recent decades, there have been signifi cant changes in the way corporate innovation is performed. They include changes in the innovation process, fl ex- ibility to outsource innovation activities, and most importantly, the location of innovation. There are mainly two new trends: First, location of globally strategic R&D by the multinational corporations (MNCs) in some developing countries; second, more recently, some companies from the emerging econo- mies have also started performing R&D to develop products and services for global markets. These trends are occurring in a dynamic business environment that consists of mutually reinforcing economic and technological changes. These trends have managerial implications for companies and policy implica- tions for the emerging economies where such R&D is performed, as well as for the industrialized home countries of the companies. Further, innovative products and services resulting from R&D activities in emerging economies seem to better address the needs of consumers at the bottom-of-the-pyramid in other developing countries. Global Innovation in Emerging Economies examines the dynamics of the globalization processes and the emergence of new locations for innova- tion and its implications. Exploring twenty in-depth case studies of MNCs, local companies, and research institutes/universities based in Brazil, China, India, and South Africa (the so-called BRICS Group), Prasada Reddy devel- ops a conceptual framework of the evolution of globalization of corporate R&D. This unique books addresses many issues including the context for location of global R&D in emerging economies by MNCs and the driving forces behind this trend, performance of global R&D by companies from emerging economies, and national and corporate implications of these new trends for innovation systems. Prasada Reddy is a faculty member at the Research Policy Institute, Lund University, Sweden. He also worked at the Centre for Entrepreneurship, University of Oslo, Norway. He has been a consultant to several multilat- eral organizations. His broad areas of work include: foreign direct invest- ments, industrialization, innovation, and intellectual property rights. Routledge Studies in Innovation, Organization and Technology 1. Innovation in the U.S. Service 9. Mobility and Technology in the Sector Workplace Michael P. Gallaher, Albert N. Link and Edited by Donald Hislop Jeffrey E. Petrusa 10. Energizing Management Through 2. Information and Communications Innovation and Entrepreneurship Technologies in Society European Research and Practice E-Living in a Digital Europe Edited by Milé Terziovski Edited by Ben Anderson, Malcolm Brynin and Yoel Raban 11. Innovating for Sustainability Green Entrepreneurship in Personal 3. The Innovative Bureaucracy Mobility Bureaucracy in an Age of Fluidity Luca Berchicci Alexander Styhre 12. Organizational Capital 4. Innovations and Institutions Modelling, Measuring and An Institutional Perspective on the Contextualising Innovative Efforts of Banks and Edited by Ahmed Bounfour Insurance Companies Patrick Vermeulen and Jorg Raab 13. User-Innovation Barriers to Democratization and IP 5. Knowledge and Innovation in Licensing Business and Industry Victor R. G. Braun and Cornelius The Importance of Using Others Herstatt Edited by Håkan Håkansson and Alexandra Waluszewski 14. Working on Innovation Edited by Christophe Midler, Guy 6. Knowledge and Innovation Minguet and Monique Vervaeke A Comparative Study of the USA, the UK and Japan 15. Organization in Open Source Helen Brown Communities At the Crossroads of the Gift and 7. Industrial Innovation in Japan Market Economies Edited by Takuji Hara, Norio Evangelia Berdou Kambayashi and Noboru Matsushima 16. Theory and Practice of Triple 8. Managing and Marketing Radical Helix Model in Developing Countries Innovations Issues and Challenges Marketing New Technology Edited by Mohammed Saad and Girma Birgitta Sandberg Zawdie 17. Global Innovation in Emerging Economies Prasada Reddy This page intentionally left blank Global Innovation in Emerging Economies Prasada Reddy New York London International Development Research Centre Ottawa • Cairo • Dakar • Montevideo • Nairobi • New Delhi • Singapore First published 2011 by Routledge 270 Madison Avenue, New York, NY 10016 Simultaneously published in the UK by Routledge 2 Park Square, Milton Park, Abingdon, Oxon OX14 4RN Routledge is an imprint of the Taylor & Francis Group, an informa business Published in association with the International Development Research Centre PO Box 8500, Ottawa, ON K1G 3H9, Canada www.idrc.ca / [email protected] ISBN 978-1-55250-504-5 (ebk) © 2011 Prasada Reddy The right of Prasada Reddy to be identified as author of this work has been asserted by him in accordance with sections 77 and 78 of the Copyright, Designs and Patents Act 1988. Typeset in Sabon by IBT Global. Printed and bound in the United States of America on acid-free paper by IBT Global. All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or here- after invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Trademark Notice: Product or corporate names may be trademarks or registered trade- marks, and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data Global innovation in emerging economies / by Prasada Reddy. p. cm. — (Routledge sutides in innovation, organizations, and technology ; 17) Includes bibliographical references and index. 1. Creative ability in business—Developing countries—Case studies. 2. Research, Industrial—Developing countries—Case studies. 3. Globalization—Developing countries—Case studies. I. Title. HD53.R415 2011 338'.064091724—dc22 2010028437 ISBN13: 978-0-415-87966-8 (hbk) ISBN13: 978-0-203-83367-4 (ebk) In Memory of My Parents Akepati Chengal Reddy and Akepati Kamalamma This page intentionally left blank Contents List of Figures xi List of Tables xiii List of Abbreviations xv Foreword xix Preface xxiii Acknowledgements xxv 1 Introduction 1 2 Global Business Environment 18 3 Globalization of Innovation—A Conceptual Framework 41 4 Innovation Environment in Emerging Economies 66 5 Global Innovation in India 108 6 Global Innovation in China 143 7 Global Innovation in Brazil 168 8 Global Innovation in South Africa 193 9 Implications for Innovation Systems 212 10 Innovations in Emerging Economies: Implications for Other Developing Countries (South-South Dimension) 236 11 Summary and Conclusions 251 Notes 263 Bibliography 269 Index 283 This page intentionally left blank Figures 2.1 Drug discovery and development process. 24 2.2 Chip design fl ow chart. 26 3.1 Globalization of corporate R&D—actor network. 59 3.2 Internationalization of corporate R&D in the 1960s and the 1970s. 63 3.3 Globalization of corporate R&D in the 1980s and the 1990s. 64 5.1 Innovation system of Motorola India. 114 6.1 Innovation system of Intel China Research Center. 153 6.2 Innovation system of HCR&D (Hitachi China). 158 6.3 Innovation system of Hanwang Technologies (China). 166 7.1 Innovation system of Motorola Brazil. 173 7.2 Innovation system of Rhodia Brazil. 177 8.1 Innovation system of DaimlerChrysler/CSIR Innovation System (South Africa). 200 8.2 Innovation system of the Naledi3d Factory (South Africa). 209 This page intentionally left blank Tables 4.1 Scientifi c Publications and GDP per Capita 69 4.2 SCI Citations and GDP per Capita 70 4.3 Number of US Patents and GDP per Capita 70 4.4 Technological Intensity of Brazilian and Indian Exports (%) (1989–2004) 73 4.5 Annual Cost of Employing a Chip Design Engineer (US$), 2002 75 5.1 Questionnaire Survey—The Driving Forces for Location of R&D in India 140 5.2 Questionnaire Survey—Type of R&D Unit and Driving Forces for Its Location 141 6.1 Intel’s R&D Laboratories and Their Features 150 This page intentionally left blank Abbreviations API Active Pharmaceutical Ingredient ARCI Astra Research Center India ASEAN Association of South East Asian Nations BITs Bilateral Investment Treaties BRICs Countries Brazil, Russia, India & China CAD Computer Aided Design CAE Computer Aided Engineering CAM Computer Aided Manufacturing CAS Chinese Academy of Sciences CDMA Code Division Multiple Access CITI Cape IT Initiative CMM Capability Maturity Model CoE Center of Excellence CRO Contract Research Organization CSIR Council for Scientifi c and Industrial Research CTU Corporate Technology Unit DST Department of Science and Technology EIU Economist Intelligence Unit EU European Union FDI Foreign Direct Investment FTA Free Trade Agreement G6 Countries US, Japan, UK, Germany, France & Italy GATS General Agreement on Trade in Services GATT General Agreement on Tariffs and Trade GcP Good Clinical Practice xvi Abbreviations GDP Gross Domestic Product GMP Good Manufacturing Practice GNP Gross National Product GPD Global Product Development GSM General System for Mobile Communication GTU Global Technology Unit HCR&D Hitachi (China) Research & Development Corporation HEI Higher Education Institution HP Hewlett-Packard IC Integrated Circuit ICRC Intel China Research Center ICT Information and Communication Technologies IDRC International Development Research Centre IICT Indian Institute of Chemical Technologies IIL Internationally Interdependent Laboratory IISc Indian Institute of Science IIT
Recommended publications
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • Trends in Vaccine Development
    ADVERTISEMENT FEATURE NATUREJOBS SPOTLIGHT ON VACCINES Trends in vaccine development How are public-private partnerships, low-cost manufacturers and new technology afecting the vaccine field? “The vaccine field BILL GATES is a handy person to grow over the next few years. the virus was identifed in 1984, to have in your corner, which In the United States, demand researchers were optimistic they is going to enlarge bodes well for those committed to will increase by around 7 percent could formulate a vaccine quickly. vaccine research. In January 2010 annually until 2015, according to a As HIV proved resilient, hopes for substantially beyond the philanthropist called for a 2011 report published by industry a fast response faded and by the SPOTLIGHT ON IMMUNOLOGY / VACCINES ON IMMUNOLOGY SPOTLIGHT “decade of vaccines” and pledged analysts Freedonia. “It’s probably early 1990s several research groups the traditional US$10 billion for vaccine research the best growth area right now in and companies had abandoned and development (R&D) and infectious disease,” says Steve Projan, the search for a vaccine. preventive vaccine.” distribution. Te Bill & Melinda senior vice president of R&D in It became clear that a new Gates Foundation funding will the innovative medicines unit at model of vaccine development was Rafi Ahmed, Emory Vaccine Center boost an already burgeoning feld. vaccine manufacturer MedImmune. needed, one that could bridge the Although vaccines comprise Te industry is being shaped by gap between the public and private a small portion of the global increased collaboration between the sectors and focus on the developing pharmaceutical market — 2 percent public and private sectors, the rise world.
    [Show full text]
  • Welcome NOTE President
    2015 welcome NOTE from the president EXECUTIVE COMMITEE MEMBERS Mr. Mahendra Suhardono President Bio Farma, Indonesia Mr. Rajender Kumar Suri Dr. Akira Homma Vice President Treasurer Panacea Biotech Limited, India Bio-Manguinhos (Fiocruz),Brazil Mr. Rayasam Prasad Ms. Meng Li Mr. Patrick Tippoo Biological E. Limited, India China National Biotec Group Co.Ltd., China The Biovac Institute, South Africa Mr. Juliman Dr. Steven Gao Mr. Adar Poonawalla GAVI Board Alternate Xiamen Innovax Biotech Co. Ltd., China GAVI Board Representative Bio Farma, Indonesia Serum Institute of India Ltd., India Member Organizations’ Geographical Presence Argentina Bangladesh Brazil Cuba Egypt India Indonesia IR of Iran Mexico P.R. China Republic of Korea Saudi Arabia South Africa Taiwan Thailand Vietnam Name of the company : Arab Company for Pharmaceutical Products (Arabio) Head of Institution : Dr. Majed Saeed Bahatheq (Arabio CEO) Established : Arabio is a limited liability company established in 2005 Location : Saudi Arabia Overview of the company Arabio is a biopharmaceutical company specialized in human vaccines, and other biopharmaceuticals. It is the first biopharmaceutical company in the Gulf Cooperation Council (GCC). The size and scope of activities intended to be made in Arabio would make Arabio the first biological company of its kind in the Middle East. Arabio aims to bring to the markets of the Middle East, North Africa, and high quality products that comply with the international quality standards. Arabio has production lines of pre-filled syringes, liquid vials and lyophilized vials from the best global machines suppliers to make high quality products and meet cGMP & international standards. Description of ARABIO capabilities – Biological sterile manufacturing – PFS and vial filling – PFS and vial blister packaging Arabio Partners: 1.
    [Show full text]
  • PDF: 300 Pages, 5.2 MB
    The Bay Area Council Economic Institute wishes to thank the sponsors of this report, whose support was critical to its production: The Economic Institute also wishes to acknowledge the valuable project support provided in India by: The Bay Area Council Economic Institute wishes to thank the sponsors of this report, whose support was critical to its production: The Economic Institute also wishes to acknowledge the valuable project support provided in India by: Global Reach Emerging Ties Between the San Francisco Bay Area and India A Bay Area Council Economic Institute Report by R. Sean Randolph President & CEO Bay Area Council Economic Institute and Niels Erich Global Business/Transportation Consulting November 2009 Bay Area Council Economic Institute 201 California Street, Suite 1450 San Francisco, CA 94111 (415) 981-7117 (415) 981-6408 Fax [email protected] www.bayareaeconomy.org Rangoli Designs Note The geometric drawings used in the pages of this report, as decorations at the beginnings of paragraphs and repeated in side panels, are grayscale examples of rangoli, an Indian folk art. Traditional rangoli designs are often created on the ground in front of the entrances to homes, using finely ground powders in vivid colors. This ancient art form is believed to have originated from the Indian state of Maharashtra, and it is known by different names, such as kolam or aripana, in other states. Rangoli de- signs are considered to be symbols of good luck and welcome, and are created, usually by women, for special occasions such as festivals (espe- cially Diwali), marriages, and birth ceremonies. Cover Note The cover photo collage depicts the view through a “doorway” defined by the section of a carved doorframe from a Hindu temple that appears on the left.
    [Show full text]
  • Panacea Biotec Receives $24.32M Award from UN Agencies
    Panacea Biotec receives $24.32M award from UN Agencies 23 December 2019 | News | By Manbeena Chawla Easyfive-TT (DTwP-HepB-Hib) was introduced by Panacea Biotec as world’s first fully liquid wP-based pentavalent vaccine in Indian market in 2005. New Delhi based biotechnology company Panacea Biotec has received Awards worth USD 24.32 Million (Over Rs.170 crores) from U.N. Agencies (UNICEF and PAHO) for supply of its Easyfive-TT, a fully liquid WHO prequalified Pentavalent Vaccine. UNICEF award is for year 2020 and award of PAHO is for three (3) years i.e. 2020-2022. Pediatric vaccination plays an important role to achieve Sustainable Development Goals set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births. Pentavalent vaccine protects children against five deadly diseases; Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b – becoming the foundation of paediatric immunization programs across the world. Easyfive-TT (DTwP-HepB-Hib) was introduced by Panacea Biotec as world’s first fully liquid wP-based pentavalent vaccine in Indian market in 2005. With WHO prequalification in 2008, over 100 million doses have been supplied to more than 50 countries globally. Easyfive-TT is ready for use without further preparation by healthcare workers in the field, which offers major healthcare advantages in countries with challenging infrastructure and hygiene problems. Panacea Biotec has contributed significantly for Children’s Health and has partnered with WHO, UNICEF & PAHO in their efforts to maximize coverage of vaccines under the Expanded Program on Immunization (EPI) in developing countries.
    [Show full text]
  • Manufacturing Permission of Human Vaccines Year 2021
    Manufacturing Permission of Human Vaccines Year 2021 S. No. Name of Firm Name of Molecule Indication Date Approved 1 M/s Serum Institute ChAdOx1 nCoV-19 For Restricted use in emergency Permission No. of India Pvt. Ltd. Corona Virus Vaccine situation: MF/BIO/21/000001 dated 212/2, Off. Soli (Recombinant) For active immunization of 03.01.2021 Poonawalla Road, individuals of ≥18 years old for the Hadapsar Pune, prevention of corona virus disease Maharashtra, India. (COVID-19) when administered in two doses schedule. The second dose should be administered between 4 to 6 weeks after the first dose. However, there is data available for administration of the second dose up to 12 weeks after the first dose from the overseas studies. 2 M/s Bharat Biotech Whole Virion Inactivated For Restricted use in emergency Permission No. International Corona Virus Vaccine, situation in clinical trial mode: MF/BIO/21/000002 dated Limited, Sy. No. [BBV152] For active immunization against 03.01.2021 230, 231 & 235, Corona Virus Disease (COVID-19) Genome Valley, for age ≥12 years when Shameerpet administered in two doses interval Mandal, Medchal- of day 0 & day 28. Malkajgiri District, Telangana-500078, India. Manufacturing Permission of Human Vaccines Year 2020 S. No. Name of Firm Name of Molecule Indication Date Approved 1 M/s Biological E. Typhoid Vi Conjugate For active immunization against MF/BIO/20/000001 dated Limited, Plot No. 1, Vaccine, IP infection caused by Salmonella 28.01.2020 Phase II, Biotech typhi in infants, children, Park, Kolthur adolescents and adults aged ≥ 6 Village, Shameerpet months to ≤ 45 years.
    [Show full text]
  • Annual Report 17-18 Initial Pages for Web.Cdr
    Contents Safe Harbour Statement Corporate Information 01 This report contains forward-looking statements, which may be identied by their use of words like Tribute to Late Shri Ravinder Jain 02 ‘plans’, ‘expects’, ‘will’, ‘anticipates’, ‘believes’, Vision, Mission & Values 03 ‘intends’, ‘projects’, ‘estimates’, or other words of similar meaning. All statements that address Chairman's Message 04 expectations or projections about the future, Panacea Biotec at a Glance 06 including but not limited to statements about Company’s future growth drivers, product Financial Highlights 07 development, market position and expenditures Core Strengths 08 are forward looking statements. Forward looking statements are based on certain assumptions and Management Discussion & Analysis 10 expectations for future events. The Company may Directors' Report 25 not guarantee that these assumptions and expectations are accurate and will be realised. The Corporate Governance Report 49 Company’s actual results, performance or Auditors' Report on Standalone achievements could thus differ materially from Financial Statements 66 those projected in any forward-looking Standalone Financial Statements 72 s t ate m e nt s. Th e Co m p a ny a s s u m e s n o responsibility to publicly amend, modify, revise Auditors' Report on Consolidated any forward-looking statements, on the basis of Financial Statements 106 any subsequent developments, information and Consolidated Financial Statements 110 events. Mr. Soshil Kumar Jain, Chairman (Sitting) along with his colleagues on the Board and other officials (from left) Mr. Mahipat Singh, Mr. Vinod Goel, Mr. N. N. Khamitkar, Mr. O. P. Kelkar, Mr. Mukul Gupta, Mr. K. M. Lal, Dr.
    [Show full text]
  • Julie Miloud Kaddar Vaccine 2
    This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues. Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited. In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier’s archiving and manuscript policies are encouraged to visit: http://www.elsevier.com/copyright Author's personal copy Vaccine 28 (2010) 2115–2121 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine The role of emerging manufacturers in access to innovative vaccines of public health importanceଝ Julie B. Milstien a,∗, Miloud Kaddar b a University of Maryland School of Medicine, Geographic Medicine, 685 West Baltimore Street, Baltimore, MD 21201-1509, United States b Department of Immunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva 27, Switzerland article info abstract Article history: The role of developing country manufacturers in assuring global access to innovative vaccines was com- Received 13 December 2009 pared to the situation in 2005. These producers now supply over 60% of traditional vaccines doses globally Accepted 14 December 2009 and an increasing value (up to 15% in 2007) of innovative products. More suppliers are now strong play- Available online 29 December 2009 ers in global market, and an even larger group has potential to do so.
    [Show full text]
  • Panacea Biotec Limited (CIN: L33117PB1984PLC022350) Regd
    Panacea Biotec Limited (CIN: L33117PB1984PLC022350) Regd. Office: Ambala - Chandigarh Highway, Lalru - 140 501, Punjab, India Corp. Office: B-1 Extn./G-3, Mohan Co-operative Indl. Estate, Mathura Road, New Delhi - 110 044, India Website: www.panaceabiotec.com E-mail: [email protected] Tel: +91 11 41679000 Fax: +91 11 41679070 NOTICE OF EXTRAORDINARY GENERAL MEETING NOTICE is hereby given that an Extraordinary General Meeting of the Members of Panacea Biotec Limited (“the Company”) will be held on Friday, June 25, 2021 at 11:30 A.M. through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”), to transact the following businesses: SPECIAL BUSINESS: 1. Raising of funds by way of issue of equity shares and / or other securities To consider and, if thought fit, to pass the following resolution, as a Special Resolution: “RESOLVED THAT pursuant to the provisions of Sections 23, 42, 62(1)(c) and all other applicable provisions, if any, of the Companies Act, 2013 read with the rules made thereunder including the Companies (Prospectus and Allotment of Securities) Rules, 2014 and the Companies (Share Capital and Debentures) Rules, 2014, (including any amendment(s), statutory modification(s) or re-enactment(s) thereof, for the time being in force) (“Act”), in accordance with the provisions of the Memorandum and Articles of Association of the Company and pursuant to the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR
    [Show full text]
  • Panacea Biotec Partners with GAVI
    Panacea Biotec partners with GAVI 11 July 2011 | News Image not found or type unknown New Delhi-based Panacea Biotec became the first company in the world to introduce a fully liquid pentavalent vaccine, EasyFive, in the year 2005. Panacea has pledged its support to the cause of GAVI alliance by deciding to reduce the cost of EasyFive to the tune of 10 to 15 percent in coming years. This effort would increase the access of vaccines to millions of children. After introduction of EasyFive in developing countries in the year 2008, the price of pentavalent vaccines have decreased by 18 percent in 2010. The new vaccine price reductions are expected to help in the donor support for GAVI & contribute towards reducing GAVI's funding challenge. Launched in 2000, the GAVI Alliance is a global health partnership representing stakeholders in immunization from both private and public sectors, developing world and donor governments, private sector philanthropists such as the Bill & Melinda Gates Foundation, the financial community, developed and developing country vaccine manufacturers, research and technical institutes, civil society organizations and multilateral organizations like the World Health Organization (WHO), the United Nations Children's Fund (UNICEF) and the World Bank. The combined demand of all pediatric vaccines worldwide is estimated to grow up toImage 7,200 not found crore or by type 2012. unknown The pentavalent vaccine market is estimated to cross a mark ofImage 4,500 not foundcrore, or outtype ofunknown which UN agencies are likely to procure vaccines worth more than Image1,912 not crorefound orby type the unknown end of 2011.
    [Show full text]
  • Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG
    EN Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 11/01/2001 Also available in the CELEX database Document No 301M2192 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 11.01.2001 SG(2000)D/285020 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information ARTICLE 6(1)(b) DECISION omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case No COMP/M.2192 – SmithKline Beecham/Block Drug Notification of 17.11.2000 pursuant to Article 4 of Council Regulation No 4064/89 1. On 17 November, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (“the Merger Regulation”), by which the UK company, SmithKline Beecham plc (“SB”) notified its intention to acquire sole control over the US company, Block Drug Company Inc. (“Block Drug”), through purchase of shares. 2. Following examination of the notification, the Commission has concluded that the notified operation falls within the scope of the said Council Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA agreement.
    [Show full text]
  • List of Participants
    LIST OF PARTICIPANTS AT THE 11th ANNUAL GENERAL MEETING & CONFERENCE OF THE DEVELOPING COUNTRIES VACCINE MANUFACTURERS NETWORK ON 13 – 16 SEPTEMBER 2010, AT NOVOTEL CONVENTION CENTER, HYDERABAD, ANDHRA PRADESH, INDIA. MEMBERS OF THE DCVMN: Organization S.No. Name of the Member Organization No. 1 1 Dr. Ella, Krishna, M Bharat Biotech International Limited, Chairman & Managing Director Genome Valley, Shameerpet (M), Hyderabad, Andhra Pradesh, India. 500 078 2 Dr. Krishna Mohan, V Bharat Biotech International Limited President Genome Valley, Shameerpet (M), Hyderabad, Andhra Pradesh, India. 500 078 3 Mr. Prasad, Sai D. Bharat Biotech International Limited, Vice President Genome Valley, Shameerpet (M), Hyderabad, Andhra Pradesh, India. 500 078 4 Dr. Harshavardhan, G.V.J.A Bharat Biotech International Limited, Director - Rotavirus Vaccine Genome Valley, Shameerpet (M), Development Project Hyderabad, Andhra Pradesh, India. 500 078 5 Dr. Srinivas, V.K Bharat Biotech International Limited, Vice President Genome Valley, Shameerpet (M), Hyderabad, Andhra Pradesh, India. 500 078 6 Dr. Kamaraj, G Bharat Biotech International Limited, General Manager: Production Genome Valley, Shameerpet (M), Hyderabad, Andhra Pradesh, India. 500 078 7 Mr. Gopinathan, K Bharat Biotech International Limited, Assistant General Genome Valley, Shameerpet (M), Manager, Quality Control. Hyderabad, Andhra Pradesh, India. 500 078 8 Mr. Venkatesan, R Bharat Biotech International Limited, Assistant General Manager, Genome Valley, Shameerpet (M), Production. Hyderabad, Andhra Pradesh, India. 500 078 2 9 Ms. Datla, Mahima Biological E. Limited, Sr. Vice President 18/1&3, Azamabad, Hyderabad, India. 500 020 10 Mr. Mantena, Narender Dev Biological E. Limited, Sr. Vice President – SBD 18/1&3, Azamabad, Hyderabad, India. 500 020 11 Mr.
    [Show full text]